On August 24, 2022 Provectus (OTCQB: PVCT) reported that the Company has expanded its sponsored research program with Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Health Science Center (UTHSC) in Memphis, Tennessee to investigate Provectus’ pharmaceutical-grade rose bengal for the treatment of anti-fungal and anti-oral bacterial infections (Press release, Provectus Biopharmaceuticals, AUG 24, 2022, View Source [SID1234618614]). Provectus’ innovatively-assembled and proprietary rose bengal is the lead member of a class of the Company’s small molecules called halogenated xanthenes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of this new sponsored research, the Kurosu team plans to evaluate the in vitro activity of Provectus’ rose bengal against different fungal strains and to conduct susceptibility tests against fungal and bacterial mouth microbes.

The Kurosu team has previously shown the favorable tolerability of the Company’s rose bengal as a topical application under different types of normal light, and the molecule’s in vitro activity against a range of different Gram-positive bacteria and against biofilms. These data and conclusions were noted in Kurosu et al.’s 2022 Molecules article entitled "Antibacterial Activity of Pharmaceutical-Grade Rose Bengal: An Application of a Synthetic Dye in Antibacterial Therapies." The Kurosu team is currently developing a journal manuscript of their prior study of the molecule’s in vitro activity against Gram-negative bacteria.